New diabetes clinical trial: Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy

Published on: May 22, 2019 at 07:00PM
Conditions:   Type 2 Diabetes;   Ketonemia
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Sitagliptin 100mg
Sponsor:   The University of Hong Kong
Recruiting